Abstract

Resistance to antibiotics is an increasingly serious threat to global public health and its management translates to significant health care costs. The validation of new Gram-negative antibacterial targets as sources for potential new antibiotics remains a challenge for all the scientists working in this field. The interference with bacterial Quorum Sensing (QS) mechanisms represents a potentially interesting approach to control bacterial growth and pursue the next generation of antimicrobials. In this context, our research is focused on the discovery of novel compounds structurally related to (S)-4,5-dihydroxy-2,3-pentanedione, commonly known as (S)-DPD, a small signaling molecule able to modulate bacterial QS in both Gram-negative and Gram-positive bacteria. In this study, a practical and versatile synthesis of racemic DPD is presented. Compared to previously reported syntheses, the proposed strategy is short and robust: it requires only one purification step and avoids the use of expensive or hazardous starting materials as well as the use of specific equipment. It is therefore well suited to the synthesis of derivatives for pharmaceutical research, as demonstrated by four series of novel DPD-related compounds described herein.

Highlights

  • Bacterial chemical communication allows bacteria to coordinate their gene expression and act as a population [1–5]

  • We describe the set-up of a new protocol for ofof racemic and its its application to the synthesis of four novel small libraries of DPD-related compounds

  • Analytical, preparative HPLC and Electron Spray Ionization (ESI) mass spectra were performed on an Agilent UHPLC (1290 Infinity, Santa Clara, CA, USA) and an Agilent Prep-HPLC (1260 Infinity), both equipped with a Diode Array Detector and a Quadrupole MS

Read more

Summary

A Versatile Strategy for the Synthesis of

Silvia Stotani 1,2 , Viviana Gatta 3 , Federico Medda 1,† , Mohan Padmanaban 1 , Anna Karawajczyk 1,‡ , Päivi Tammela 3 , Fabrizio Giordanetto 1,§ , Dimitrios Tzalis 1 and Simona Collina 2, *. Current address: Centurion Biopharma Corporation, Engesserstraße 4, 79108 Freiburg im Breisgau, Germany. Current address: Selvita S.A., Park Life Science, Bobrzyňskiego 14, 30-348 Krakow, Poland. Received: 16 September 2018; Accepted: 3 October 2018; Published: 6 October 2018

Introduction
Discussion
Synthesis of DPD and Ph-DPD
Synthesis
16. Reagents
The reaction obtain and was
The andand conditions:
Evaluation ofafter
Biological Evaluation of Synthetized Compounds
Chemistry
Biology
LsrK Overexpression and Purification
DPD Activity Evaluation
Screening of DPD-Related Compounds
Conclusions

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.